We are delighted to announce the release of the twelfth edition of our Sustainability Report. This significant milestone highlights over a decade of consistent and transparent commitment to responsible business practices and the ongoing pursuit of a more sustainable value chain in the healthcare industry.
The 2025 Sustainability Report provides a comprehensive and detailed overview of the company’s environmental, social, and governance (ESG) performance. It demonstrates how sustainability is deeply integrated into the strategy and daily operations, showcasing not only the progress made but also our future goals for addressing global challenges. From innovations in materials and production processes to a focus on employee well-being and community contributions, the report highlights initiatives and outcomes that strengthen our position as a reliable and forward-thinking partner.
“The publication of the twelfth edition of our Sustainability Report is a significant milestone for Palladio Group,” said Adrea Argentin, Corporate QHSE & Sustainability Director. “This report not only reflects our progress, but also underscores our firm commitment to driving change in the pharmaceutical packaging sector. We remain convinced that a responsible approach is not just ethical, but also crucial for creating long-term value for all our stakeholders.”
Key highlights of this edition of the Sustainability Report include:
Progress in managing the environmental footprint: in 2024, the Group expanded its reporting on indirect emissions (Scope 3) to cover all 15 applicable categories outlined by the GHG Protocol, achieving a more comprehensive view of the impact across the entire value chain. Emission reduction targets for Scope 1, 2, and 3 have been set in line with the Science Based Target Initiative (SBTi), with the aim of obtaining SBTi approval for these targets in 2025.
Responsible supply chain management: in 2024, 100% of the new suppliers added to the Vendor List were assessed through a questionnaire that included Corporate Social Responsibility requirements.
Investments in human capital and community: in 2024, the Group delivered 16,972 hours of employee training. We also supported social initiatives such as I Bambini delle Fate and Dynamo Camp, and launched several corporate volunteering programs.
Innovation and development of sustainable packaging solutions: the company continues to invest significantly in research and development, focusing on projects that reduce environmental impact. These include the development of tamper-evident paperboard solutions that eliminate the need for plastic labels, as well as internal trays made from cardboard or pressed paper to replace polymer alternatives.
We invite stakeholders, customers, partners, and all interested parties to download and review the full Sustainability Report, available at the following link.
The release of this twelfth edition reaffirms our commitment to operating with transparency and responsibility, while contributing to a more ethical, innovative, and sustainable pharmaceutical supply chain.
